Our findings illustrate that PLAGL2 serves as a crucial regulatory factor of the β-catenin-ZEB1 molecular mechanisms, and may be a promising therapeutic target for CRC anti-metastatic strategies. This evidence concerns the gene PLAGL2 and colorectal carcinoma.